Kane Biotech Inc (TSE:KNE)
:KNE
KNE Stock Chart & Stats
C$0.03
<C$0.01(4.76%)
At close: 4:00 PM EST
C$0.03
<C$0.01(4.76%)
Day’s Range― - ―
52-Week RangeC$0.03 - C$0.10
Previous CloseN/A
Volume199.87K
Average Volume (3M)112.95K
Market Cap
C$5.46M
Enterprise ValueC$6.38M
Total Cash (Recent Filing)C$939.06K
Total Debt (Recent Filing)C$2.30M
Price to Earnings (P/E)―
Beta0.83
Next Earnings
May 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding181,846,560
10 Day Avg. Volume120,057
30 Day Avg. Volume112,955
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)-9.04
Price to Sales (P/S)7.08
P/FCF Ratio-3.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Patented Antimicrobial TechnologyKane Biotech’s focus on patented antimicrobial and anti-biofilm technologies represents a durable competitive advantage. Patents and specialized science underpin barriers to entry, support pricing power in niche clinical, veterinary and industrial markets, and enable long-term licensing and product differentiation.
Diversified Revenue StreamsMultiple revenue channels—direct product sales, licensing/royalties, and partnership milestone potential—reduce single-market dependence. This diversification supports steadier cash inflows over time, allows risk sharing with partners, and creates recurring royalty revenue that can stabilize finances if product adoption grows.
Improving Free Cash Flow GrowthReported free cash flow growth of ~5.15% in the trailing period signals initial progress toward self-funded operations. If sustained, rising FCF can reduce the need for external financing, support R&D and commercialization, and materially improve long-term liquidity and operational resilience.
Bears Say
Severe Revenue DeclineA near 69% revenue drop is a structural red flag: it erodes economies of scale, weakens market positioning, and constrains reinvestment in R&D and commercialization. Sustained top-line contraction undermines the company’s ability to translate its IP and partnerships into durable, profitable growth.
Deep Negative ProfitabilityExtremely negative net and operating margins indicate persistent operating losses that are unlikely to be resolved without structural revenue recovery or cost realignment. Continued losses deplete capital, hinder strategic investment, and increase dependency on dilutive or expensive financing over the medium term.
Weak Balance Sheet And High LeverageNegative equity and an effective debt-to-equity of -11.09 reflect severe capitalization issues and high leverage, reducing financial flexibility. This raises refinancing risk, limits ability to fund commercialization or R&D, and can deter large strategic partners that require stronger balance sheet stability.
KNE FAQ
What was Kane Biotech Inc’s price range in the past 12 months?
Kane Biotech Inc lowest stock price was C$0.03 and its highest was C$0.10 in the past 12 months.
What is Kane Biotech Inc’s market cap?
Kane Biotech Inc’s market cap is C$5.46M.
When is Kane Biotech Inc’s upcoming earnings report date?
Kane Biotech Inc’s upcoming earnings report date is May 21, 2026 which is in 41 days.
How were Kane Biotech Inc’s earnings last quarter?
Currently, no data Available
Is Kane Biotech Inc overvalued?
According to Wall Street analysts Kane Biotech Inc’s price is currently Overvalued.
Does Kane Biotech Inc pay dividends?
Kane Biotech Inc does not currently pay dividends.
What is Kane Biotech Inc’s EPS estimate?
Kane Biotech Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Kane Biotech Inc have?
Kane Biotech Inc has 181,846,560 shares outstanding.
What happened to Kane Biotech Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Kane Biotech Inc?
Currently, no hedge funds are holding shares in TSE:KNE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Kane Biotech Inc
Kane Biotech Inc., a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops pet oral care products under the StrixNB and bluestem brands; animal and human wound care solutions under the DispersinB name; shampoos for dogs, cats, and horses under the Alosera name; and medical device coatings under the Aledex name. It also offers scalp care products under the DermaKB brand name, wound care products under the Coactiv+ brand name, as well as other products under the goldstem, silkstem, and DermaKB Biofilm brand names. Kane Biotech Inc. was incorporated in 2001 and is based in Winnipeg, Canada.
Technical Analysis
Aptose Biosciences
―
XORTX Therapeutics Inc
―
Quest Pharmatech
―
BioVaxys Technology
―
Doseology Sciences
―
Options Prices
Currently, No data available
---